Moderna (NASDAQ:MRNA) Releases Earnings Results, Beats Estimates By $0.06 EPS

Moderna (NASDAQ:MRNA) issued its earnings results on Friday. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06, FiscalAI reports. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted ($2.13) EPS.

Here are the key takeaways from Moderna’s conference call:

• 2026 revenue and cost outlook improved: Moderna reiterated revenue growth of up to 10% and lowered its full-year cost-of-sales and R&D forecasts by $100 million each, while reducing expected cash costs by $200 million to approximately $4 billion.
• Flu vaccine advances toward potential approval: mRNA-1010 received a unanimous positive recommendation from the FDA advisory committee, with a U.S. PDUFA decision expected August 5 and regulatory reviews ongoing in Europe, Canada, and Australia.
• mNEXSPIKE showed strong initial commercial traction: The COVID vaccine captured approximately 24% of the U.S. retail market in its first season and about 34% among adults aged 65 and older, supported by encouraging real-world effectiveness data against hospitalization.
• Norovirus vaccine development faces a delay: mRNA-1403 did not meet statistical criteria for early success at its interim analysis, requiring enrollment of an additional cohort and another seasonal period to collect sufficient cases; the trial remains blinded.
• Pipeline milestones remain active: Moderna expects an interim analysis for the fully enrolled phase III intismeran melanoma study in the second half of 2026 and data from its registrational propionic acidemia study in the fourth quarter, while expanding oncology programs into Lynch syndrome and solid tumors.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $54.82 on Friday. The firm has a market capitalization of $21.75 billion, a price-to-earnings ratio of -6.86 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The business’s 50 day simple moving average is $59.37 and its 200-day simple moving average is $52.51. Moderna has a 12 month low of $22.28 and a 12 month high of $85.60.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MRNA. Piper Sandler upped their price objective on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, June 26th. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Morgan Stanley boosted their target price on shares of Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 8th. Bank of America upped their price target on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Finally, Royal Bank Of Canada increased their price target on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $40.00.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 119,406 shares of company stock valued at $5,928,762 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. Empowered Funds LLC grew its stake in Moderna by 2.6% in the 4th quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after acquiring an additional 353 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Moderna by 21.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 387 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund raised its position in Moderna by 6.2% during the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,334 shares of the company’s stock worth $241,000 after acquiring an additional 546 shares during the last quarter. Mackenzie Financial Corp raised its position in Moderna by 5.1% during the fourth quarter. Mackenzie Financial Corp now owns 11,767 shares of the company’s stock worth $357,000 after acquiring an additional 566 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Moderna by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 110,812 shares of the company’s stock valued at $2,862,000 after purchasing an additional 687 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.